Letrozole and Anastrozole in Early Breast Cancer Post-menopausal Patients in Oncology Department at Suez Canal University Hospital | ||
| Suez Canal University Medical Journal | ||
| Article 6, Volume 21, Issue 1, March 2018, Pages 40-49 PDF (799.8 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/scumj.2018.43356 | ||
| Authors | ||
| Manar Montasser* ; Ehab M Hassanin; Soheir E Abdelmohsen; Maha L Zamzam | ||
| Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Suez Canal University, Egypt | ||
| Abstract | ||
| Background:There are limited data in the literature comparing the efficacy of aromatase inhibitors in postmenopausal hormonal receptor positive early breast cancer patients. Aim: To compare the efficacy of letrozole and anastrozole in hormone-receptor positive postmenopausal breast cancer patients. Patients and Methods: A retrospective study with a mean follow-up period of 64 months (about 5 years) for 74 files of early invasive postmenopausal breast cancer hormonal receptor positive patients; 39 received letrozole and 35 received anastrozole, considering TTP as primary end point, and OS as second end points. Results: Letrozole is not superior to anastrozole during the first 55 months of treatment (80% PFS at 5th year), and 80% OS benefit at 6th year.. Overweight patients had better (90% PFS at 5th year) than obese patients (60% PFS at 5th year). Conclusion: Letrozole is not superior to anastrozole in efficacy in early invasive hormonal receptor positive breast cancer postmenopausal patients during the first 5 years of treatment; however, Letrozole 2nd line after tamoxifen is superior to anastrozole 2nd line after tamoxifen in treating obese patients with early invasive hormone receptor positive breast cancer. | ||
| Keywords | ||
| Suvival; TTP; PFS; AI | ||
|
Statistics Article View: 294 PDF Download: 754 |
||
